MeiraGTx Holdings Plc (MGTX)

In November 2025, MeiraGTx announced a strategic collaboration with Eli Lilly and Company in ophthalmology and reported its third-quarter 2025 financial results. In December 2024, the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to AAV2-hAQP1. In March 2026, the company announced robust financial results for the fourth quarter and full-year 2025, and the FDA granted Breakthrough Therapy designation to AAV2-hAQP1, leading to a share price increase. In April 2026, MeiraGTx announced the pricing of a $100 million offering of ordinary shares, acquired botaretigene sparoparvovec (bota-vec), presented positive three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1, and saw Perceptive Advisors and affiliates increase their ownership to 12.6%. Also in April 2026, MeiraGTx detailed a $200 million Hologen CNS gene therapy pact, and analysts downgraded their revenue forecasts for 2026.

Information regarding specific demand seasonality for MeiraGTx Holdings Plc's products and services is not explicitly available. Its revenue and financial performance are more influenced by research and development milestones, clinical trial progress, regulatory approvals, and strategic partnerships rather than seasonal fluctuations. The company is in a growth phase, and its financial metrics reflect the challenges typical for firms at the clinical development stage before reaching profitability.

MeiraGTx Holdings Plc (MGTX) is a clinical-stage genetic medicines company focused on developing gene and cell therapies for serious inherited and acquired diseases within the biotechnology industry. The company has a broad pipeline with late-stage clinical programs in ophthalmology, Parkinson's disease, and radiation-induced xerostomia, including AAV-AIPL1 for Leber congenital amaurosis 4 (LCA4), AAV-CNGB3 and AAV-CNGA3 for achromatopsia, and AAV-GAD for Parkinson's disease. MeiraGTx utilizes proprietary gene regulation technologies and has in-house manufacturing capabilities for GMP viral vector production.

MeiraGTx Holdings Plc is incorporated in the Cayman Islands and trades on the Nasdaq Global Select Market. It operates through subsidiaries in the United Kingdom and Ireland, with facilities supporting research, development, clinical operations, and manufacturing. The company also operates in the United States and the European Union, with its head office located in New York, USA.

MeiraGTx maintains a positive brand reputation in the biotechnology sector due to its innovative work in genetic medicines and strategic collaborations. Analysts have a consensus "Moderate Buy" rating and see significant upside potential in its stock price. Strategic collaborations with Eli Lilly and Company and Hologen Limited strengthen its research and development efforts. The company's focus on addressing unmet medical needs in severe diseases enhances its standing.

MeiraGTx Holdings Plc has significant institutional ownership, with approximately 70.3% held by institutions and 4.61% by individuals. Major institutional owners and shareholders include Sanofi, Perceptive Advisors Llc (holding 12.6% with warrants), Johnson & Johnson Innovation - JJDC, Inc., Rubric Capital Management LP, Adage Capital Partners Gp, L.l.c., Prosight Management, LP, Millennium Management Llc, BlackRock, Inc., 683 Capital Management, LLC, and Morgan Stanley.